ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Parkinson's Disease

Parkinson's Disease Clinical Trial

Official title:

A Feasibility Study to Evaluate Safety and Initial Effectiveness of ExAblate Transcranial MR Guided Focused Ultrasound for Unilateral Thalamotomy in the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson's Disease.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01772693
• Other study ID #: PD001
• Status: Completed
• Phase: N/A
• Start date: September 2012
• Est. completion date: March 2019

Study information

• Verified date: July 2020
• Source: InSightec
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a feasibility study to evaluate the safety and initial effectiveness of unilateral ExAblate thermal ablation of the Vim thalamic nucleus of subjects suffering from medication-refractory, idiopathic, tremor-dominant PD, using the ExAblate Transcranial system compared to a Sham Vim thalamotomy procedure.

Data will be collected to establish the basic safety of this type of treatment as the basis for later studies that will evaluate its full clinical efficacy. The Sham treatment data will be used to evaluate placebo effect from treatment.

Description:

Subjects who sign informed consent and pass all eligibility criteria will be randomized to a treatment assignment. During treatment, the assigned treatment (ExAblate Transcranial or Sham ExAblate Transcranial)will be delivered. Subjects are followed in a blinded fashion for three (3) months. After the 3-month assessment, subjects will be unblinded and told their treatment assignment. Subjects receiving Sham ExAblate Transcranial treatment who still meet criteria will be crossed over and receive an active ExAblate Transcranial treatment. Subjects will be followed for up to two (2) years. Follow-up at 1 week, 1 month, 3 months, 6 months, 9 months, 12 months and up to two (2) years includes Unified Parkinson's Disease Rating Scale (UPDRS) scoring, mental and cognitive functional testing and questionnaires.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 27
• Est. completion date: March 2019
• Est. primary completion date: April 26, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years and older

Eligibility

Inclusion Criteria:

• Men and women, age 30 years and older

• Subjects who are able and willing to give informed consent and able to attend all study visits

• Subjects with a diagnosis of idiopathic PD as confirmed from clinical history and examination by a movement disorder neurologist at the site

• Subject demonstrates a severe resting tremor or postural/action as measured by UPDRS

• Subject exhibits a significant disability from their PD tremor despite medical treatment

• Subjects should be on a stable dose of all PD medications for 30 days prior to study entry

• Subject is able to communicate sensations during the ExAblate Transcranial procedure

Exclusion Criteria:

• Subjects with unstable cardiac status

• Subjects exhibiting any behavior(s) consistent with ethanol or substance abuse

• Severe hypertension

• Subjects with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations, etc.

• Known intolerance or allergies to the MRI contrast agent including advanced kidney disease or severely impaired renal function

• Significant claustrophobia that cannot be managed with mild medication

• Current medical condition resulting in abnormal bleeding and/or coagulopathy

• Receiving anticoagulant (e.g. warfarin) or antiplatelet (e.g. aspirin) therapy within one week of focused ultrasound procedure or drugs known to increase risk or hemorrhage

• History of intracranial hemorrhage

• History of multiple strokes, or a stroke within past 6 months

• Subjects who are not able or willing to tolerate the required prolonged stationary supine position during treatment

• Are participating or have participated in another clinical trial in the last 30 days

• Subjects unable to communicate with the investigator and staff

• Subjects with a history of seizures within the past year

• Subjects with brain tumors

• Subjects with intracranial aneurysms requiring treatment or arterial venous malformations (AVMs) requiring treatment

• Subjects who have had deep brain stimulation or a prior stereotactic ablation of the basal ganglia

Related Conditions & MeSH terms

• Parkinson Disease
• Parkinson's Disease

Intervention

Device:
• ExAblate Transcranial MRgFUS
ExAblate Transcranial MR Guided Focused Ultrasound
• Sham ExAblate Transcranial MRgFUS
Sham ExAblate Transcranial MR Guided Focused Ultrasound

Locations

Country	Name	City	State
United States	University of Virginia	Charlottesville	Virginia
United States	Swedish Medical Center	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
InSightec

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Adverse Events	Evaluate of adverse events (AEs) associated with the ExAblate Transcranial thalamotomy of medication-refractory, tremor-dominant PD during the ExAblate treatment.; Primary safety analyses are reported in the adverse events module.	Month 3
Secondary	Tremor Motor Score Percent Change From Baseline.	The percent change from baseline to Month 3 follow-up in upper extremity Tremor-Motor scores for the treated side is a sub-scale of Clinical Rating Scale for Tremor (CRST) Part A and Part B sum that was used to measure treated-side upper extremity tremor changes over time. Tremor-motor scores range from 0-32 points. Individual subject's scores at Baseline and 3 Months were used to calculate percent change from baseline and averaged across subjects. High percent change from baseline is better (shows improvement).	Baseline, Month 3
Secondary	Tremor Motor Scores - Clinical Rating Scale for Tremor - Treated Side Upper Extremity Parts A & B.	Upper extremity Tremor-Motor score for the treated side is a sub-scale of Clinical Rating Scale for Tremor (CRST) Part A and Part B sum that measures treated-side upper extremity tremor changes over time. Tremor-motor scores range from 0-32 points for each side with lower scores being a better outcome. Subject's Tremor-Motor scores for the test and sham control groups were averaged at each study visit.	Baseline, Month 3, Month 12
Secondary	Functional Disabilities - Clinical Rating Scale for Tremor Part C - Functional Disabilities	The Clinical Rating Scale for Tremor (CRST) Part C is a measure of functional disability due to tremor. The Clinical Rating Scale for Tremor Part C consists of 8 items each scored from 0 to 4. Thus, the total score summed ranges from 0 to 32 and provides an overall assessment of activities of daily living. Low scores on the Clinical Rating Scale for Tremor (CRST) Part C are better. Low scores show improvement in functional disabilities compared to higher scores.	Baseline, Month 3, Month 12